- Amorepacific’s fermented L-glutamate GABA powder obtains Korean FDA approval as a sleep-promoting functional ingredient, becoming Amorepacific’s sixth individually recognized ingredient with KFAD
- Amorepacific’s supplement brand VITAL BEAUTIE to launch a new sleep health supplement next month
Amorepacific R&I Center
Amorepacific announced that fermented L-glutamate GABA powder , a sleep-quality improving ingredient developed by the Amorepacific R&I Center, has been acknowledged by the Korean Ministry of Food and Drug Safety (KMFDS) as an individually recognized functional ingredient.
Individually recognized ingredients are acknowledged for efficacy and safety by the KMFDS through a strict screening process, including surveys of years of research and development by the manufacturer and human application testing. The fermented L-glutamate GABA powder is Amorepacific’s sixth individually recognized ingredient.
Amorepacific developed the fermented L-glutamate GABA powder upon discovering that GABA, a sleep-related substance produced naturally in the brain, can be supplemented to help improve sleep quality. Safe for all adult groups, including the elderly, the power can enhance sleep quality with repeated intake.
According to Amorepacific’s health and beauty supplements brand VITAL BEAUTIE, human application tests have shown that fermented L-glutamate GABA powder can improve seven sleep-related indicators, including sleep efficiency, total sleep time, and total awake time. The brand plans to introduce a new supplement product based on the fermented L-glutamate GABA powder next month.
As demand for sound sleep is rising steadily every year, interest in sleep-promoting functional foods is also increasing. VITAL BEAUTIE anticipates that the newly registered ingredient, fermented L-glutamate GABA powder , along with substances already available in the market, including lactium, rice bran alcohol extracts, and ecklonia chamomile extracts, will benefit people who have trouble sleeping.
Like
3Recommend
2Thumbs up
2Supporting
0Want follow-up article
0